ONO-7018

DRUG2 trials

Sponsors

Ono Pharmaceutical Co., Ltd.

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinNon Hodgkin Lymphoma

Phase 1

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

TerminatedNCT05515406

Ono Pharmaceutical Co., Ltd.Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin

Start: 2023-02-13End: 2025-08-13Updated: 2026-05-29

A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

TerminatedNCT06622226

Ono Pharmaceutical Co., Ltd.Non Hodgkin Lymphoma

Start: 2024-11-27End: 2026-04-28Updated: 2026-07-29

Related Papers

A phase I, first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.

Journal of Clinical Oncology2024-06-01

ONO-7018, a First-in-Class MALT1 Inhibitor, Provides Novel Therapeutic Strategies for B Cell Malignancies: Overcoming BTK Inhibitor Acquired Resistance and Enhancing the Antitumor Effect of BTK Inhibitors

Blood2023-11-021 citations